A Phase 2 Intensification Study of BIT225, a Human Immunodeficiency Virus-1 Vpu Inhibitor, in HIV-1 Infected Individuals Initiating Combination Antiretroviral Therapy (cART).

Trial Profile

A Phase 2 Intensification Study of BIT225, a Human Immunodeficiency Virus-1 Vpu Inhibitor, in HIV-1 Infected Individuals Initiating Combination Antiretroviral Therapy (cART).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Aug 2017

At a glance

  • Drugs BIT 225 (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Sponsors Biotron
  • Most Recent Events

    • 28 Aug 2017 According to a Biotron media release, the trial is in progress and scheduled for completion in the second half of 2017.
    • 31 Jul 2017 Planned End Date changed from 31 Oct 2017 to 4 Jan 2018.
    • 27 Jul 2017 According to a Biotron media release, early results from this trial are anticipated in October 2017 after trial completion.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top